ADCC Target HER2 Negative Assay Ready Cells

iLite ADCC Target HER2 Negative Assay Ready Cells Developed and Manufactured by Svar Life Science

The iLite ® ADCC Target HER2 (-) Assay Ready Cells:

• is included as part of the iLite® ADCC Target HER2 Activity Set
• can be used as negative controls together with iLite ADCC Effector (V) Assay Ready Cells and iLite ADCC Target HER2 (+) Assay Ready Cells for measuring the ADCC activity of anti-HER2 antibodies.

Content: >250 µL of Assay Ready Cells diluted in DMEM with 20% heat inactivated fetal bovine serum (FBS), mixed 1:1 with cryoprotective medium from Lonza (Cat. No 12-132A).

Storage: -80°C, Cells should be used within 30 min of thawing.
For Research Use Only

---

Key benefits of iLite® ADCC Activity Assays

---

• Unparalleled sensitivity
• High serum tolerance
• Normalization read-out included
• Negative control available for screening of unspecific activity
• Easy to use – no culturing required on target or effector cells

---

Background

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism whereby pathogenic cells are lysed by lymphocytes, most often Natural Killer (NK) cells. The mechanism involves binding of antibodies to surface antigens on the pathogen. Crosslinking of these antibodies to NK cells through the binding of the Fc-portion to Fc receptors on the NK cells leads to activation of the NK cell and formation of an immune synapse with the pathogenic cell. The NK cell releases cytotoxic granules containing granzymes and perforin into the synapse, leading to apoptosis of the targeted cell.

Breast cancer is the most common cancer in women worldwide, and the second most common cancer overall. Survival rates have improved in the recent years, and stratification of patients into subgroups has vastly improved treatment options for many patients. As an example, patients with HER2 positive breast cancer generally have a poor prognosis, but treatment with trastuzumab, a monoclonal antibody targeting the HER2 receptor, has shown to increase both overall survival and disease free survival when given together with chemotherapy. Trastuzumab’s mechanism of action is mediated in part by inducing ADCC when crosslinking HER2 positive cells with the patient’s immune cells. The drug was FDA approved for treatment of breast cancer patients in 1998, and many biosimilars are currently in development.

---

Products Related to iLite ADCC Target HER2- Assay Ready Cells

iLite ADCC Target HER2+ Assay Ready Cells
iLite anti-HER2 ADCC Activity Set
iLite Effector V Assay Ready Cells

EagleBio的5α-雄甾烷-3α，17β-二醇葡糖醛酸化物是C19类固醇，缩写为3α-DiolG，5α二醇G或简称为α二醇G。它主要作为睾丸激素和二氢睾丸激素（DHT）的代谢产物生产。它主要在目标外围组织（例如皮肤）中产生，尤其是在毛囊周围。大量的3α-DiolG刺激会导致过多的头发形成，特别是在女性通常不存在头发的地方。近年来，在研究患有特发性多毛症的妇女的临床研究人员中，人们对这种类固醇的测量越来越感兴趣。已知是3α-DiolG前体的类固醇包括脱氢表雄酮（DHEA），硫酸脱氢表雄酮（DHEAS），二氢睾丸酮（DHT），雄烯二酮和睾丸激素。已显示只有3α-DiolG随多毛症增加而随治疗减少。这种相关性在多囊卵巢综合征（PCO）患者中也得到了证明。3α-DiolG的测定因此被证明是多种方式的有用指标，包括监测特发性多毛症和PCO妇女的治疗进展。此外，接受环孢霉素A治疗的糖尿病患者（无论男女）均显示3α-DiolG水平升高，这种副作用导致以前无毛的区域出现了头发。3α-DiolG的测定因此被证明是多种方式的有用指标，包括监测特发性多毛症和PCO妇女的治疗进展。此外，接受环孢霉素A治疗的糖尿病患者（无论男女）均显示3α-DiolG水平升高，这种副作用导致以前无毛的区域出现了头发。3α-DiolG的测定因此被证明是多种方式的有用指标，包括监测特发性多毛症和PCO妇女的治疗进展。此外，接受环孢霉素A治疗的糖尿病患者（无论男女）均显示3α-DiolG水平升高，这种副作用导致以前无毛的区域出现了头发。